Bril V - Search Results

1

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: bril v. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.

2

Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis.

Zinman LH, O'Connor PW, Dadson KE, Leung RC, Ngo M, Bril V. Zinman LH, et al. Among authors: bril v. Muscle Nerve. 2006 May;33(5):694-6. doi: 10.1002/mus.20511. Muscle Nerve. 2006. PMID: 16421884

3

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.

Zinman L, Ng E, Bril V. Zinman L, et al. Among authors: bril v. Neurology. 2007 Mar 13;68(11):837-41. doi: 10.1212/01.wnl.0000256698.69121.45. Neurology. 2007. PMID: 17353471 Clinical Trial.

4

Surrogate therapeutic outcome measures in patients with myasthenia gravis.

Zinman L, Baryshnik D, Bril V. Zinman L, et al. Among authors: bril v. Muscle Nerve. 2008 Feb;37(2):172-6. doi: 10.1002/mus.20908. Muscle Nerve. 2008. PMID: 17918748 Clinical Trial.

5

A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.

Jensen P, Bril V. Jensen P, et al. Among authors: bril v. J Clin Neuromuscul Dis. 2008 Mar;9(3):352-5. doi: 10.1097/CND.0b013e3181660807. J Clin Neuromuscul Dis. 2008. PMID: 18344718 Clinical Trial.

6

IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.

Zinman L, Bril V. Zinman L, et al. Among authors: bril v. Ann N Y Acad Sci. 2008;1132:264-70. doi: 10.1196/annals.1405.038. Ann N Y Acad Sci. 2008. PMID: 18567877

7

The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers.

Barnett C, Katzberg H, Nabavi M, Bril V. Barnett C, et al. Among authors: bril v. J Clin Neuromuscul Dis. 2012 Jun;13(4):201-5. doi: 10.1097/CND.0b013e31824619d5. J Clin Neuromuscul Dis. 2012. PMID: 22622164

8

Fcγ receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis.

Barnett C, Grinberg Y, Ghani M, Rogaeva E, Katzberg H, St George-Hyslop P, Bril V. Barnett C, et al. Among authors: bril v. J Clin Neuromuscul Dis. 2012 Sep;14(1):1-6. doi: 10.1097/CND.0b013e31825c566b. J Clin Neuromuscul Dis. 2012. PMID: 22922574

9

Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.

Barnett C, Wilson G, Barth D, Katzberg HD, Bril V. Barnett C, et al. Among authors: bril v. J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):94-7. doi: 10.1136/jnnp-2011-301449. Epub 2012 Nov 15. J Neurol Neurosurg Psychiatry. 2013. PMID: 23154126 Clinical Trial.

10

IVIG and PLEX in the treatment of myasthenia gravis.

Bril V, Barnett-Tapia C, Barth D, Katzberg HD. Bril V, et al. Ann N Y Acad Sci. 2012 Dec;1275:1-6. doi: 10.1111/j.1749-6632.2012.06767.x. Ann N Y Acad Sci. 2012. PMID: 23278570

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page